Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
pharmaphorum14h
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
FierceBiotech14h
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Le Lézard22h
Chang Gung Memorial Hospital Unveils Cellular Therapy: A Beacon of Hope for Cancer Treatment
Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising ...
The Pharma Letter23h
Gilead and Merck tout first weekly oral HIV treatment
have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Le Lézard1d
TRYX Announces Exclusive Partnership with Pro Gamers Group for EU Market
We are thrilled to announce that TRYX has entered into a strategic partnership with Pro Gamers Group, making them the ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
New Data On Twice-yearly Lenacapavir For HIV Prevention Announced At HIVR4P 2024
7 October 2024 (Lima, Peru) – New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention ...
Investing14d
Gilead reports 96% HIV prevention with new drug lenacapavir
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) shared results from the Phase 3 PURPOSE 2 trial, showcasing the efficacy of lenacapavir, an injectable HIV-1 capsid inhibitor, in preventing ...